Nrx Pharmaceuticals Inc (NRXP) Stock Price, Quote & News

Company Profile

NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder, and chronic pain. Its lead drug candidates include NRX-101, an oral, fixed dosed combination of D-cycloserine and lurasidone for suicidal treatment-resistant bipolar depression in patients with sub-acute suicidal ideation and behavior in phase 2 trial; and NRX-100, a preservative-f...

Industry: Biotechnology

Sector: Healthcare

Phone: 484 254 6134

Website: www.nrxpharma.com

Address:

1201 Orange Street, Suite 600, Wilmington, United States

Outcomes Apr. 8 at 12:29 PM

$IBRX .....very interesting as it relates to $NRXP ! https://www.fchampalimaud.org/centre-restorative-neurotechnology/digital-neurotherapeutics-centre

0 · Reply

FounderV Apr. 8 at 3:04 AM

$NRXP God bless Dr. Javitt and all the holders of the NRXP...

2 · Reply

jacksparo Apr. 7 at 10:43 PM

$SLS $IBRX $OCGN $GEVO $NRXP Stay tuned for the big day tomorrow my great team and followers 📈📈📈✅✅✅!

1 · Reply

Outcomes Apr. 7 at 6:27 PM

$IBRX $MRNA $PFE $NRXP .....mRNA BAD. 'Turbo-cancers'. 🙏 🙏 https://www.straitstimes.com/business/biontech-to-wind-up-singapore-vaccine-manufacturing-plant-in-early-2027

1 · Reply

SoloBueno Apr. 7 at 11:59 AM

$NRXP Upon reviewing the stock charts and analyst predictions subsequent to the SPAC, it is evident that a substantial disparity has consistently existed between the analyst price targets, the CEO's assertions, DavidBG's predictions, and actual performance. Over the years, the only apparent beneficiaries appear to be short sellers, the CEO and his family, and DavidBG.

0 · Reply

surfsup11 Apr. 7 at 2:26 AM

$NRXP Sravato has a black box warning for sedation,disossociation,potential for misuse and abuse and increased suicidal thoughts and behaviors. It profited 780 million the first 9 months in 2024. How about NRXP may have a couple of approvals with none of these risks and no box box warning and reduce suicidal ideation. If it goes its going to go.

0 · Reply

Outcomes Apr. 6 at 11:28 PM

$IBRX $NRXP .....been saying it for years, mRNA BAD https://www.straitstimes.com/business/biontech-to-wind-up-singapore-vaccine-manufacturing-plant-in-early-2027

2 · Reply

Geraldgenofranco1953 Apr. 6 at 7:27 PM

$NRXP Best stock for two years hold.

1 · Reply

NetworkNewsWire Apr. 6 at 6:39 PM

PsychedelicNewsBreaks – $NRXP Receives FDA Labeling Feedback for Preservative-Free Ketamine Application https://ibn.fm/eYLSl

0 · Reply

focafoca99 Apr. 6 at 6:23 PM

$NRXP says the FDA's label feedback on its preservative-free ketamine application was limited to minor formatting changes, which sounds like a constructive step.

0 · Reply

NRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Labeling Alignment for NRx's Preservative-Free Ketamine Application

Mar 30, 2026, 7:00 AM EDT - 9 days ago

Hope Therapeutics, an NRx Pharmaceuticals Subsidiary (Nasdaq:NRXP), Announces Strategic Partnership with Emobot to Integrate its AI-Powered “Depression Thermometer” Across its Interventional Psychiatry Network

Mar 24, 2026, 7:00 AM EDT - 15 days ago

NRx Pharmaceuticals (Nasdaq:NRXP) Reports Full-Year 2025 Results and Highlights Key Regulatory and Commercial Progress

Mar 19, 2026, 7:00 AM EDT - 20 days ago

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) to Report Full Year 2025 Financial Results and Provide a Corporate Update on March 24, 2026

Mar 17, 2026, 7:00 AM EDT - 22 days ago

NRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Bioequivalence Determination by Office of Generic Drugs for NRx's Preservative-Free Ketamine Application

Mar 16, 2026, 7:00 AM EDT - 23 days ago

NRx Pharmaceuticals (Nasdaq:NRXP) Confirms Path to New Drug Application with Real World Data and Broader Proposed Indication for NRX-100 (ketamine) Following Type C FDA Meeting

Mar 9, 2026, 7:00 AM EDT - 4 weeks ago

HOPE Therapeutics, an NRx Subsidiary (Nasdaq:NRXP) Announces opening of Palm Beach, FL Clinic offering One Day treatment for Depression and PTSD

Mar 2, 2026, 7:00 AM EST - 5 weeks ago

NRx Pharmaceuticals (Nasdaq: NRXP) Appoints Prof. Joshua Brown MD, PhD, as Chief Medical Innovation Officer

Feb 17, 2026, 7:00 AM EST - 7 weeks ago

NRx Pharmaceuticals (Nasdaq:NRXP) Announces Path to New Drug Application with Real World Data and Broader Proposed Indication for NRX-100 (ketamine) Following Type C FDA Meeting

Jan 16, 2026, 7:03 AM EST - 2 months ago

NRx Pharmaceuticals (Nasdaq:NRXP) Announces 2025 Annual Meeting Date and Record Date

Jan 14, 2026, 7:03 AM EST - 3 months ago

NRx Pharmaceuticals (Nasdaq:NRXP) Announces 70,000 Patient Data on Real World Use of Ketamine for Treatment of Suicidal Depression to be Submitted to the FDA in Support of NRX-100 Approval

Jan 5, 2026, 6:57 AM EST - 3 months ago

NRx Pharmaceuticals (Nasdaq:NRXP) and neurocare Group AG Announce Joint Offering of Neuroplastic Therapy Targeting Depression, PTSD, and other mental health afflictions

Dec 18, 2025, 7:05 AM EST - 3 months ago

NRx Pharmaceuticals (Nasdaq:NRXP) announces elimination of all balance sheet debt following equity conversion

Dec 3, 2025, 7:00 AM EST - 4 months ago

NRx Pharmaceuticals to discuss new NRX-101 pipeline indication for augmentation of Transcranial Magnetic Stimulation

Dec 2, 2025, 8:30 AM EST - 4 months ago

NRx Pharmaceuticals Announces US Food and Drug Administration (FDA) Receipt of ANDA for KETAFREE™, a Preservative-Free IV Ketamine

Dec 2, 2025, 7:30 AM EST - 4 months ago

NRx Pharmaceuticals (NASDAQ: NRXP) and HOPE Therapeutics to Host Corporate Update Call

Dec 1, 2025, 8:03 AM EST - 4 months ago

NRx Pharmaceuticals (NASDAQ:NRXP) and HOPE Therapeutics to Present at NobleCon21 - Noble Capital Markets' Twenty First Annual Emerging Growth Equity Conference

Nov 17, 2025, 8:03 AM EST - 5 months ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 12, 2025, 8:31 AM EST - 5 months ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report Third Quarter 2025 Financial Results on November 17, 2025

Nov 10, 2025, 8:03 AM EST - 5 months ago

HOPE Therapeutics, Inc., an NRx Pharmaceuticals Subsidiary, Announces First-in-Florida Initiation of One Day (ONE-D) Depression Treatment in Partnership with Ampa Health

Oct 20, 2025, 8:03 AM EDT - 6 months ago

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Inclusion of Cohen & Associates, LLC of Sarasota, FL into the HOPE Network and Appointment of Dr. Rebecca Cohen as HOPE Medical Director

Oct 6, 2025, 8:03 AM EDT - 6 months ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Present at Noble Capital Markets October 2025 Emerging Growth Virtual Equity Conference

Sep 29, 2025, 8:03 AM EDT - 6 months ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Re-Files Abbreviated New Drug Application (ANDA) for KETAFREE™, Preservative-Free IV Ketamine

Sep 24, 2025, 8:03 AM EDT - 7 months ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives Notification of US Food and Drug Administration Approval of Suitability Petition for NRx's Proposed Strength of Preservative-Free Ketamine

Sep 8, 2025, 8:17 AM EDT - 7 months ago

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Complete the Acquisition of Dura Medical; Initial Acquisition in Network of Interventional Psychiatry Clinics

Sep 3, 2025, 8:03 AM EDT - 7 months ago

NRx Pharmaceuticals (NASDAQ:NRXP) to Participate in a Fireside Chat at H.C. Wainwright's 27th Annual Global Investment Conference on Monday, September 8th

Sep 2, 2025, 1:19 PM EDT - 7 months ago

UPDATE -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Selected to Present at the 2025 Global Passion Project with Matthew Rockefeller, Sponsored by Rockefeller Global Family Office

Sep 2, 2025, 8:41 AM EDT - 7 months ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Selected to Present at the 2025 Global Passion Project with Matthew Rockefeller and Rockefeller Capital

Aug 27, 2025, 8:03 AM EDT - 8 months ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces Expanded Access Policy for NRX-100 (preservative-free ketamine)

Aug 18, 2025, 8:10 AM EDT - 8 months ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 13, 2025, 6:06 PM EDT - 8 months ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reschedules Second Quarter 2025 Financial Results Release to August 19, 2025

Aug 11, 2025, 4:05 PM EDT - 8 months ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report Second Quarter 2025 Financial Results on August 14, 2025

Aug 11, 2025, 8:03 AM EDT - 8 months ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Granted FDA Fast Track Designation for NRX-100 for Suicidal Ideation in Patients with Depression, including Bipolar Depression

Aug 8, 2025, 8:03 AM EDT - 8 months ago

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Receipt of Final Clearance to Proceed to Closing of Dura Medical Acquisition from Florida's Agency for Health Care Administration (AHCA)

Aug 4, 2025, 8:03 AM EDT - 8 months ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces Filing of a Citizen Petition with the US Food and Drug Administration Seeking Removal of Benzethonium Chloride from Ketamine Products

Jul 29, 2025, 8:03 AM EDT - 9 months ago

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Join Fireside Chat at BTIG Virtual Biotech Conference July 29 - 30, 2025

Jun 26, 2025, 8:03 AM EDT - 10 months ago

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Agreement to Acquire Interest in Cohen and Associates, LLC for HOPE's Network of Interventional Psychiatry Clinics

Jun 23, 2025, 8:03 AM EDT - 10 months ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces Filing of Commissioner's National Priority Voucher Application for Intravenous Ketamine (NRX-100)

Jun 16, 2025, 8:03 AM EDT - 10 months ago

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) and HOPE Therapeutics, Inc. Announce Strategic Investor Relations Partnership with astr partners

Jun 12, 2025, 8:03 AM EDT - 10 months ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and HOPE Therapeutics, Inc. to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

Jun 5, 2025, 8:03 AM EDT - 10 months ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Files Abbreviated New Drug Application (ANDA) for Preservative-Free IV Ketamine

May 15, 2025, 4:03 PM EDT - 11 months ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 15, 2025, 10:15 AM EDT - 11 months ago

HOPE Therapeutics, Inc. a subsidiary of NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces Signing of Term Sheet for $7.8 Million Debt Financing to Fuel HOPE Clinic Acquisitions

May 13, 2025, 8:03 AM EDT - 11 months ago

HOPE Therapeutics, Inc. and NRx Pharmaceuticals (NASDAQ:NRXP) Announce Signing of Definitive Agreement to Purchase Kadima Neuropsychiatry Institute; Foundational Acquisition for the HOPE Network of Interventional Psychiatry Clinics

May 12, 2025, 8:03 AM EDT - 11 months ago

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Report First Quarter 2025 Financial Results on May 15, 2025

May 6, 2025, 8:03 AM EDT - 1 year ago

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Host Investor Event at Mar-A-Lago Club on May 8, 2025

May 5, 2025, 8:03 AM EDT - 1 year ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Files Patent Application for NRX-100, its Proprietary, Preservative Free Formulation of IV Ketamine

Apr 30, 2025, 8:46 AM EDT - 1 year ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces FDA Award of Filing Fee Waiver for Upcoming NRX-100 (preservative free ketamine) New Drug Application to Treat Patients with Suicidal Depression

Apr 21, 2025, 8:01 AM EDT - 1 year ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and HOPE Therapeutics™, Inc.to Participate in an H.C. Wainwright @ Home Fireside Discussion on Tuesday, April 22, 2025

Apr 3, 2025, 8:03 AM EDT - 1 year ago

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Signing of a Term Sheet for Strategic Investment from a Global Medical Device Manufacturer into HOPE

Outcomes Apr. 8 at 12:29 PM

$IBRX .....very interesting as it relates to $NRXP ! https://www.fchampalimaud.org/centre-restorative-neurotechnology/digital-neurotherapeutics-centre

0 · Reply

FounderV Apr. 8 at 3:04 AM

$NRXP God bless Dr. Javitt and all the holders of the NRXP...

2 · Reply

jacksparo Apr. 7 at 10:43 PM

$SLS $IBRX $OCGN $GEVO $NRXP Stay tuned for the big day tomorrow my great team and followers 📈📈📈✅✅✅!

1 · Reply

Outcomes Apr. 7 at 6:27 PM

$IBRX $MRNA $PFE $NRXP .....mRNA BAD. 'Turbo-cancers'. 🙏 🙏 https://www.straitstimes.com/business/biontech-to-wind-up-singapore-vaccine-manufacturing-plant-in-early-2027

1 · Reply

SoloBueno Apr. 7 at 11:59 AM

0 · Reply

surfsup11 Apr. 7 at 2:26 AM

0 · Reply

Outcomes Apr. 6 at 11:28 PM

$IBRX $NRXP .....been saying it for years, mRNA BAD https://www.straitstimes.com/business/biontech-to-wind-up-singapore-vaccine-manufacturing-plant-in-early-2027

2 · Reply

Geraldgenofranco1953 Apr. 6 at 7:27 PM

$NRXP Best stock for two years hold.

1 · Reply

NetworkNewsWire Apr. 6 at 6:39 PM

PsychedelicNewsBreaks – $NRXP Receives FDA Labeling Feedback for Preservative-Free Ketamine Application https://ibn.fm/eYLSl

0 · Reply

focafoca99 Apr. 6 at 6:23 PM

$NRXP says the FDA's label feedback on its preservative-free ketamine application was limited to minor formatting changes, which sounds like a constructive step.

0 · Reply

DavidBG Apr. 6 at 2:25 PM

$NRXP @SmallCapGrowth @DonDon531 Today's press release is about Ketafree (the branded generic for which an ANDA has been submitted), not NRX-100 (the novel indication for which an NDA is being finalized).

1 · Reply

SoloBueno Apr. 6 at 2:09 PM

$NRXP Is Javitt and his social media team indicating approval for Summer 2025, or is it premature speculation?

0 · Reply

SmallCapGrowth Apr. 6 at 1:35 PM

🚨 $NRXP JUST DROPPED MAJOR FDA NEWS TODAY (April 6, 2026) — Preservative-Free Ketamine ANDA Gets Labeling Alignment! NRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Labeling Alignment for NRx’s Preservative-Free Ketamine Application https://ir.nrxpharma.com/news-releases/news-release-details/nrx-pharmaceuticals-nasdaqnrxp-announces-fda-labeling-alignment ✅ Only minor formatting tweaks ✅ Final label drops THIS MONTH ✅ Summer 2026 approval targeted [b]U.S.-made supply fix while competitors are on backorder + National Priority Voucher secured. Ketamine franchise de-risked again. NRX-100 path heating up FAST! Who’s loading $NRXP before summer approval? 👀🚀[/b] #NRXP #FDA #Ketamine #Biotech #Stocks #StocksToWatch

1 · Reply

SmallCapGrowth Apr. 6 at 1:11 PM

#FrontPageStocks News: NRx Pharmaceuticals (Nasdaq: $NRXP) Announces #FDA Labeling Alignment for NRx’s Preservative-Free Ketamine Application https://www.globenewswire.com/news-release/2026/04/06/3268338/0/en/NRx-Pharmaceuticals-Nasdaq-NRXP-Announces-FDA-Labeling-Alignment-for-NRx-s-Preservative-Free-Ketamine-Application.html @frontpagestocks #nasdaq #stocks

0 · Reply

IChiGOdoranZ Apr. 6 at 12:10 PM

$NRXP News : NRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Labeling Alignment for NRx’s Preservative-Free Ketamine Application https://ir.nrxpharma.com/news-releases/news-release-details/nrx-pharmaceuticals-nasdaqnrxp-announces-fda-labeling-alignment

0 · Reply

DonDon531 Apr. 6 at 11:40 AM

$NRXP one step away from approval!!! BOOM!!!!

0 · Reply

FounderV Apr. 6 at 11:38 AM

$NRXP Bullish...

1 · Reply

Outcomes Apr. 6 at 11:20 AM

$NRXP https://ir.nrxpharma.com/news-releases/news-release-details/nrx-pharmaceuticals-nasdaqnrxp-announces-fda-labeling-alignment

0 · Reply

DARKP00L Apr. 6 at 11:05 AM

$NRXP 07:05 on Apr. 06 2026 NRx Pharmaceuticals Receives FDA Letter Regarding Comments On Minor Formatting Changes To Proposed Label For Its Preservative-Free Ketamine Product, The Company Expects To Submit Final Label In April #tradeideas

0 · Reply

FounderV Apr. 5 at 2:52 AM

$NRXP We will see...

1 · Reply

FounderV Apr. 5 at 1:54 AM

$NRXP Happy Easter!

0 · Reply

Outcomes Apr. 3 at 12:00 PM

$NRXP ....Zyesami: the rigged trial JJ knows. https://substack.com/@stopthoseshots/note/c-235425895?r=re3i2&utm_medium=ios&utm_source=notes-share-action

0 · Reply

Market Cap	74.40M
Revenue (ttm)	1.23M
Net Income (ttm)	-28.62M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	16.92
Profit Margin	-2,326.83%
Debt to Equity Ratio	0.00

Volume	693,800
Avg Vol	687,118
Day's Range	N/A - N/A
Shares Out	33.07M
Stochastic %K	40%
Beta	1.83
Analysts	Strong Sell
Price Target	$38.00